However, some studies reported that the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, initially developed as an anti-diabetes drug, might be a promising strategy for the management of HF (7–14). This evidence concerns the gene SLC5A2 and hydrops fetalis.